Résumé

Introduction: COVID 19 is a global pandemic declared by the WHO on 30/01/2020. The first case was declared in Burundi on 31 March 2020. The objective of our work was to study liver function abnormalities during SARS CoV2 and their impact on the prognosis of the disease. Methodology: This is a retrospective, single-center, descriptive and analytical study that took place over a period of 2 years (2020-2021). This study involved 115 patients who were hospitalized at the BUMEREC Hospital. Results: 155 patients had a liver test during hospitalization. The mean age of the patients was 60 years with an interval between 22 and 97 years. The male predominance with 59.50%, i.e. a sex ratio of 1.46. The most common comorbidities were hypertension and diabetes, with rates of 31.30% and 29.57% respectively. The most frequent clinical signs were: cough, fever and asthenia with respective rates of 87.83%, 73.04%, 53.91%. 74.78% had mild to moderate disease and 25.22% had severe disease. ASAT/ALT> 2N, GGT>2N and PAL>1.5 N levels were 43.47%, 20% and 9.57% of patients, respectively. Clinical worsening during hospitalization was observed in 41.74% and in-hospital mortality was 15.65%. The respective averages of AST, ALT, GGT, and PAL in deceased patients were 118, 131, 118, and 289. There is a statistically significant relationship between the depth of disruption in liver work-up and patient mortality. Conclusion: COVID-19 is frequently associated with a mild disruption of liver work. Patients with a profound abnormality in liver biology are likely to progress to serious disease.

Mot-clés :

COVID 19; cytolysis; cholestasis, Burundi